Egyptian study pits two liver cancer drug combos Head-to-Head
NCT ID NCT07669597
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks back at medical records of 50 adults in Egypt with advanced liver cancer who received one of two immunotherapy combinations: atezolizumab plus bevacizumab or durvalumab plus tremelimumab. Researchers want to see which group lives longer at 12 months and how they compare on tumor shrinkage, side effects, and quality of life. Because it uses past data, it can't prove cause and effect but may reveal real-world differences in Egyptian patients.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- atezolizumab plus bevacizumab; durvalumab plus tremelimumab
- What this could lead to
- If this study finds one regimen works better or is safer for Egyptian patients, it could help doctors choose the best first-line treatment for advanced liver cancer in that population.
- What could go wrong
- This is a small, retrospective study (only 50 patients) using existing records, so results may be less reliable than a large prospective trial. Differences in patient care or data quality could affect findings.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED OR METASTATIC HEPATOCEULLAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Sohag Oncology Center
Sohag, Egypt